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Background: Risk stratification, detection of minimal residual disease (MRD), and implementation of novel
therapeutic agents have improved outcome in acute lymphoblastic leukemia (ALL), but survival of adult patients
with T-cell acute lymphoblastic leukemia (T-ALL) remains unsatisfactory. Thus, novel molecular insights and
therapeutic approaches are urgently needed.
Methods: We studied the impact of B-cell CLL/lymphoma 11b (BCL11b), a key regulator in normal T-cell
development, in T-ALL patients enrolled into the German Multicenter Acute Lymphoblastic Leukemia Study Group
trials (GMALL; n = 169). The mutational status (exon 4) of BCL11b was analyzed by Sanger sequencing and mRNA
expression levels were determined by quantitative real-time PCR. In addition gene expression profiles generated on
the Human Genome U133 Plus 2.0 Array (affymetrix) were used to investigate BCL11b low and high expressing
T-ALL patients.
Results: We demonstrate that BCL11b is aberrantly expressed in T-ALL and gene expression profiles reveal an
association of low BCL11b expression with up-regulation of immature markers. T-ALL patients characterized by low
BCL11b expression exhibit an adverse prognosis [5-year overall survival (OS): low 35% (n = 40) vs. high 53% (n = 129),
P = 0.02]. Within the standard risk group of thymic T-ALL (n = 102), low BCL11b expression identified patients with
an unexpected poor outcome compared to those with high expression (5-year OS: 20%, n = 18 versus 62%, n = 84,
P < 0.01). In addition, sequencing of exon 4 revealed a high mutation rate (14%) of BCL11b.
Conclusions: In summary, our data of a large adult T-ALL patient cohort show that low BCL11b expression was
associated with poor prognosis; particularly in the standard risk group of thymic T-ALL. These findings can be
utilized for improved risk prediction in a significant proportion of adult T-ALL patients, which carry a high risk of
standard therapy failure despite a favorable immunophenotype.
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Improved treatment strategies, integrating risk stratification
and minimal residual disease (MRD) monitoring, have
improved survival of adult patients with acute lympho-
blastic leukemia (ALL) over the last decades [1,2]. Never-
theless, overall survival (OS) remains unsatisfactory with
about 40-70%, depending on protocol and age group.
Thus far, novel therapy approaches have mainly been de-
veloped in B-lineage ALL, where new targeted therapies
with monoclonal antibodies like Rituximab or small
molecule tyrosine kinase inhibitors (TKI) such as ima-
tinib for Philadelphia chromosome/BCR-ABL-positive
patients have been established [3-6]. In T-cell acute
lymphoblastic leukemia (T-ALL), less progress has been
made despite the introduction of nelarabine in relapsed
and refractory disease [7,8]. Other molecular driven
approaches, including γ-secretase inhibitors, have until
now been less successful [9].
In the German Multicenter Study Group for Adult ALL
(GMALL), immunologic subtypes are routinely used as
prognostic factors for the risk stratification of T-ALL.
Within the high risk group of early T-ALL patients the
recently identified subgroup of Early T-cell precursor
(ETP-) ALL has been characterized by an immature
immunophenotype with a high rate of FLT3-mutations,
suggesting a potential role for TKI in the treatment for
these high risk patients [10-12]. In contrast, T-ALL patients
with a thymic phenotype have a more favorable prog-
nosis [1] and are therefore classified as standard risk.
Nevertheless, this large group (56% of adult T-ALL) [3]
of standard risk T-ALL contains a molecularly and clin-
ically heterogeneous group of patients. Thus, novel in-
sights into the molecular stratification will further aid in
refining treatment options.
The B-cell CLL/lymphoma 11b (BCL11b) gene, a Krüppel-
like C2H2 zinkfinger transcription factor located on
chromosome 14q32.2, is a key player in physiologic
T-cell development with potential impact on T-ALL
leukemogenesis. In normal hematopoiesis, the onset of
BCL11b expression in T-cell progenitors occurs during
the onset of DN2 phase and is maintained throughout
subsequent differential stages (Figure 1) [13,14]. For sev-
eral target genes BCL11b acts as repressor (p21, p57), for
others as activator of transcription (IL-2) [15-17]. In vitro
studies demonstrated that knockdown inhibited prolifera-
tion and led to apoptosis in human T-ALL cell lines [18,19]
and a chemo-protective effect of BCL11b overexpression
was also observed [20].
In addition, BCL11b is proposed to act as haploinsuf-
ficient tumor-suppressor, as its disruption was found to
be associated with lymphomagenesis in mice [21,22]. In
humans, chromosomal translocations involving the BCL11b
gene locus were identified in patients with acute myeloid
leukemia (AML), T-ALL and T/myeloid acute bilineageleukemia [23-28]. Likewise, deletions and missense mu-
tations, disrupting gene function, were reported in 9 to
16% of pediatric T-ALL patients [29,30]. One study found
BCL11b more frequently mutated in adult patients com-
pared to children (20% vs. 5.3%) [31], with a lower mutation
rate in early immature (3.6%) and a higher rate (12%) in
cortical/mature adult T-ALL [32]. Studies on the prognostic
impact of BCL11b mutations gave diverging results: a small
study reported a favorable outcome for adult T-ALL
patients with BCL11b mutations (n = 4) [32], however,
studies in pediatric patients reported no prognostic ef-
fect of mutations [29,30].
We hypothesized that deregulated expression of BCL11b,
which is tightly regulated in normal T-cell differentiation,
and BCL11b mutations play an important role in T-ALL.
Therefore, we analyzed BCL11b mRNA expression levels in
a large cohort of adult T-ALL patients and screened for
mutations in the zinc finger region.
Results
BCL11b is heterogeneously expressed in adult T-ALL
BCL11b mRNA expression levels were not detectable in
CD34 positive hematopoietic progenitor cells or unse-
lected bone marrow (BM) samples from healthy donors,
whereas high expression levels were found in CD3 positive
mature T-cells (median: 2.5, Figure 2). In contrast, diagnos-
tic BM samples of adult T-ALL patients (n = 195) showed
an aberrant and highly heterogeneously BCL11b expression
pattern (median: 0.5 range = 0-12.3; Figure 2).
As explorative approach, we divided the samples into
BCL11b-low and BCL11b-high expression groups by
quartiles. Expression levels in the lowest quartile Q1
(≤0.2) were regarded as BCL11b-low, and samples with
levels in quartiles Q2-4 (>0.2) as BCL11b-high.
BCL11b associated global gene expression profile
To explore the underlying transcriptional profile associated
with aberrant BCL11b expression in T-ALL, we analyzed
microarray expression data of an independent cohort of 86
adult T-ALL patients [33]. Samples were classified into a
low and a high BCL11b expression group as described in
the material and methods section. We identified 229 up-
regulated probe sets (corresponding to 183 unique genes,
hypothetical genes/proteins and open reading frames) and
200 down-regulated probe sets (corresponding to 166 genes,
hypothetical genes/proteins and open reading frames) in the
BCL11b-low group compared to the BCL11b-high group
(Figure 3A, Additional file 1: Table S2 and Additional file 1:
Table S3). In the BCL11b-low group, genes reported to
be suppressed by BCL11b were highly expressed: cyclin-
dependent kinase inhibitor 1A (p21) and cyclin-dependent
kinase inhibitor 1C (p57) [15,17]. Interestingly, genes asso-
ciated with an immature stem cell-like phenotype were
up-regulated in the BCL11b-low cohort including IGFBP7,
Figure 1 BCL11b expression in the stages of normal T-cell development. In the murine model BCL11b expression begins during the
transition of DN1 to DN2 and continues throughout further differentiation steps and in mature T-cells [39]. Knockout at DN2 stage leads to a NK
like phenotype with differentiation arrest and a high proliferative potential [13]. The corresponding human T-ALL immunophenotypes are indicated.
DN = Double Negative, DP = Double Positive, NK = Natural Killer cells, ETP = Early T-cell progenitors,▲up-regulation,▼down-regulation.
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BCL11b-high group showed co-expression of markers of a
mature T-cell phenotype including several T-cell receptor
genes as well as CD8 and CD6. This was further under-
scored in gene set enrichment analysis (GSEA), in which
gene sets associated with physiological T-cell development
were enriched in BCL11b-high (P < 0.01) and genes down
regulated in normal T-cells were enriched in BCL11b-low
group (P = 0.01; Figure 3B) [37].
BCL11b expression with respect to molecular and clinical
characteristics
We further explored molecular characteristics associated
with BCL11b expression in the T-ALL GMALL patient
cohort by quantitative RT-PCR. Samples in the lowest
expression quartile (Q1; n = 49; BCL11b expression
range = 0-0.2) were compared to samples with aberrantly
high BCL11b expression levels defined as Q2-4 (n = 146;
BCL11b expression range >0.2-12.3, Additional file 1:
Table S4). In concordance with the gene expression pro-
files (GEP) data, these molecular studies by RT-PCR
confirmed IGFBP7 to be overexpressed in the BCL11b-
low compared to the BCL11b-high group. No significant
difference between BCL11b-low and BCL11b-high pa-
tients was observed for the previously described negative
prognostic factors including BAALC, ERG, and WT1
[34,38]. GATA3, a transcription factor up-regulated in
DN1 phase of normal T-cell development [39] was sig-
nificantly lower expressed in BCL11b-low (median: 2.1vs. 5.7, P < 0.01) compared to BCL11b-high patients. The
frequency of TCR rearrangements was significantly lower
(50% vs. 80%, P = 0.01) in BCL11b-low compared to the
BCL11b-high group. The BCL11b low and the high ex-
pressing groups did not differ regarding NOTCH1 or
WT1 mutation frequencies (Additional file 1: Table S4).
There was no difference with respect to age or sex of
T-ALL patients enrolled on the GMALL 06/99 and 07/03
trials, but within the BCL11b-low group significantly more
patients had a low white blood cell count (WBC; 62% vs.
18% <30.000 × 109/l WBC; P = 0.01; Table 1). Patients
with early T-ALL showed a significantly lower BCL11b
expression (median: 0.3) compared to patients with mature
(median: 0.6, P = 0.03) or thymic (median: 0.6, P = 0.01)
T-ALL (Additional file 1: Figure S1).
BCL11b expression is associated with outcome in
adult T-ALL
While there was no difference between BCL11b-low and
BCL11b-high within the overall GMALL cohort of T-ALL
patients with respect to the response to induction therapy
(Table 1), the overall survival probability of BCL11b-low
patients was significantly lower compared to BCL11b-high
patients (Q1: n = 40, 35% at 5 yrs; Q2-4: n = 129, 53%
at 5 yrs; P = 0.02; Figure 4A). When outcomes were an-
alyzed separately for each quartile, T-ALL patients with
BCL11b-low (Q1) showed an inferior outcome (Q1: n = 40;
35% OS at 5 yrs) compared to patients in the remaining
quartile groups (Q2: n = 42; 52% OS at 5 yrs; Q3: n = 42;
Figure 2 BCL11b mRNA expression in T-ALL patients and healthy donors. A heterogeneous expression pattern was observed within the
T-ALL patient samples. Samples from healthy donors had a significantly higher expression of BCL11b in CD3 positive mature T-cells than in CD34
positive progenitor cells or unselected bone marrow (BM) samples. T-ALL patients were split into BCL11b expression quartiles and patients with
low or lacking expression were combined in Q1 and patients with high expression in Q2-4. Outliers (n = 4 T-ALL patients, BCL11b expression
values: 6.3, 7.6, 9.7, 12.3) were omitted from the diagram but included in the statistical analysis. BM = bone marrow; *** P < 0.01.
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file 1: Figure S2A).
Low BCL11b defines high risk patients within the
standard risk group of thymic T-ALL
The identification of novel prognostic markers is in par-
ticular important for the largest subgroup of standard risk
thymic T-ALL. As these patients are regarded as standard
risk, allogeneic stem cell transplantation is not recom-
mended in first complete remission within GMALL trials.
In thymic T-ALL, BCL11b expression groups did not
differ in the expression levels of molecular markers includ-
ing BAALC, ERG, IGFBP7 and WT1. The BCL11b-low
group showed significantly lower expression of T-cell
regulator GATA3 compared to BCL11b-high (median Q1:1.6, median Q2-4: 5.1, P < 0.01). Significantly fewer thymic
BCL11b-low patients remained in continuous complete
remission at five years compared to BCL11b-high thymic
T-ALL patients (at 5 yrs: Q1: n = 15, 38%; Q2-4: n = 78,
72%; P = 0.02; Additional file 1: Figure S2B). Moreover,
BCL11b-low thymic T-ALL had a significantly inferior OS
compared to BCL11b-high thymic T-ALL patients: while
only 20% (n = 18) of BCL11b-low patients were alive at
5 years, the 5 year OS of the BCL11b-high group was 62%
(n = 84; P < 0.01, Figure 4B). Similar to the entire cohort,
patients with thymic T-ALL BCL11b-low (Q1) showed a
significantly inferior outcome compared to higher expres-
sion quartiles (Q1: n = 18, 20% at 5 yrs; Q2 n = 26, 67%
at 5 yrs¸ Q3 n = 18, 50% at 5 yrs; Q4 n = 30, 70% at
5 yrs; P = 0.01; Additional file 1: Figure S2C).
Figure 3 Gene expression profiles reveal an immature phenotype in BCL11b-low group. A: Heat map of two-fold or greater differentially
expressed genes between BCL11b quartile 1 (Q1) and quartiles 2-4 (Q2-4). B: Gene set enrichment analysis for differentially regulated genes in
physiological T-cell development according to their BCL11b expression. On the left side the top hundred down-regulated genes are shown, on
the right side the top hundred up-regulated genes. The lists were taken from Noversthern et al. [37].
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We sequenced BCL11b exon 4 and identified in 14%
(24/178) of the T-ALL patients protein modifying alterations
(Figure 5, Additional file 1: Table S6). A single T-ALL pa-
tient carried two mutations. Sixteen of the mutations were
point mutations with single base pair exchanges leading to
amino acid exchanges in 13 and a translation stop in three
cases. Seven patients carried deletions and two insertions
causing frame shifts. 23 of 24 mutations were either located
within zinc finger domains or had an impact on these
domains through frame shift or stop of translation, and
thus have a likely impact on protein function. Nearly
all patients with BCL11b mutations were in the BCL11b-
high group (n = 22/23, P = 0.01). The presence of BCL11bmutations was associated with the maturation stage of
the T-ALL. Of the 21 patients with BCL11b mutations,
18 were classified as thymic T-ALL (85.5%; P = 0.03;
Additional file 1: Table S7). WT1, a negative prognostic
factor, was significantly lower expressed in the BCL11b
mutated group and other known oncogenes or molecular
factors were not associated with BCL11b mutation status
(not shown). However, outcome analyses showed no signifi-
cant impact of BCL11b mutations and deletions on overall
survival (Additional file 1: Figure S3).
Discussion
During normal T-cell development, T-cell progenitors pass
through separate differentiation stages and this process is
Table 1 Clinical characteristics of GMALL T-ALL patients








15-35 yrs 27 70
36-55 yrs 13 48
56-65 yrs 0 11
Sex n.s.
Female % 20% 26%





Early n (%) 17 (42%) 23 (18%)
Mature n (%) 5 (13%) 22 (17%)
Thymic n (%) 18 (45%) 84 (65%)
Response to induction therapy n.s.
CR n (%) 37 (95%) 115 (94%)
ED n (%) 1 (3%) 3 (2%)
Failure n (%) 1 (3%) 5 (4%)
Abbreviations: CR = complete remission, ED = early death, WBC = white blood
cell count.
Bartram et al. Journal of Hematology & Oncology 2014, 7:51 Page 6 of 10
http://www.jhoonline.org/content/7/1/51tightly regulated by lineage specific transcription factors.
While onset of GATA3 and TCF-1 expression characterize
the early DN1 (ETP) phase in T-cell differentiation, BCL11b
is expressed at the later DN2 stage [39]. As a gatekeeper of
T-cell development, it is essential for the correct αβ T-cell
development [3,40]. Loss of BCL11b at various stages was
shown to induce a natural killer cell-like phenotype with a
differentiation arrest and was associated with a high prolif-
erative potential [14,40]. In addition, BCL11b is necessary
for T-cell identity maintenance. Alteration of different
stage-specific transcription factors and key regulators
of T-cell differentiation by silencing, ectopic expression or
mutations have shown to contribute in oncogenic trans-
formation in T-ALL. For example, aberrant NOTCH1 sig-
naling through activating mutations found in 50-60% of
T-ALL cases [41,42], is a prominent example of a potent
driver event in T-cell leukemogenesis. For TAL1, which
plays a key role in hematopoietic stem cell development,
rearrangements and aberrant expression were found in
T-ALL patients [43]. In this case, TAL1 expression was
positively correlated with survival in pediatric patients[44]. Likewise for the homeobox transcription factor
TXL-1 deregulation and gene locus abnormalities had been
associated with improved outcome for TXL-1-high T-ALL
patients [45]. Understanding of the molecular processes in-
volved in T-ALL pathology offers the possibility to refine
prognosis and stratify therapeutic algorithms.
For BCL11b aberrant expression levels, deletions and
mutations have been reported in T-ALL [29-32,46,47].
Here we comprehensively investigated the implications of
altered BCL11b expression and loss of function mutations
in a large cohort of adult T-ALL patients (n = 169). While
CD34+ hematopoietic progenitor cells and unselected BM
samples of healthy donors lack BCL11b expression, T-ALL
patients showed an aberrant and highly heterogonous
BCL11b expression pattern. Similar to normal T-cell
differentiation, the expression of BCL11b reflected the
maturation stage in T-ALL and thus was significantly
lower in the early compared to thymic and mature T-ALL
subgroups (Figure 1, Additional file 1: Figure S1). Analysis
of microarray expression data confirmed this observation
revealing up-regulation of genes associated with an im-
mature phenotype in BCL11b-low and an enrichment
of markers of a mature T-cell phenotype in BCL11b-
high T-ALL.
While the combined patient data suggested that BCL11b
expression reflects the differentiation arrest of leukemic
cells, expression was heterogeneously distributed and pa-
tients that lacked or had very low BCL11b expression were
found in all immunophenotypic subgroups. This suggests
that BCL11b is not just a mere marker of genetically more
differentiated blasts, but may act as a maturation dependent
tumor suppressor, which is supported in other studies
[29,30,47]. If deregulated during differentiation, disruption
of normal BCL11b function may contribute to malignant
transformation.
In this study the cohort of uniformly treated adult T-ALL
patients, the BCL11b-low subgroup had a significantly
inferior OS compared to the BCL11b-high patients. In
particular, in the standard risk group of thymic T-ALL,
BCL11b was of relevant prognostic impact: 62% of
BCL11b-high patients were alive after 5 years, whereas
survival was only 20% at 5 years in the BCL11b-low
subgroup. Remission duration was also significantly shorter
for patients within the BCL11b-low subgroup. This con-
trasts a study in pediatric T-ALL patients, which showed
that BCL11b expression had no impact on OS [30], al-
though the difference may be due to the smaller sample
size of the study and that patients were not classified
into immunophenotypic subgroups. Nevertheless, low
BCL11b expression was associated with chemotherapy
induction failure in the same study.
While immunophenotypic classification of T-ALL has
improved outcome prediction, a relevant percentage of
patients classified as standard risk based on their thymic
Figure 4 Kaplan–Meier analyses of overall survival (OS) and remission duration in T-ALL with respect to BCL11b mRNA expression.
A: T-ALL patients with low BCL11b expression showed significant inferior OS than patients with higher expression (low expression quartile Q1 vs.
high Q2-4 expression quartiles; P = 0.02; log-rank test). B: The BCL11b low expressing thymic T-ALL patients had a highly significant inferior
OS (P < 0.01).
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As thymic T-ALL on the molecular and clinical levels
compromises a highly heterogeneous cohort, it remains
essential to identify patients with a high risk of relapse
to adjust treatment stratification. Our results indicate
that thymic BCL11b-low T-ALL patients represent a
high risk subgroup which would benefit from intensi-
fied MRD monitoring and treatment stratification in-
cluding allogeneic stem cell transplantation. Since lack
of BCL11b expression proved to indicate inferior sur-
vival, we investigated disruption of the gene’s functionFigure 5 Mutations found in exon 4 of BCL11b in T-ALL. Mutation anal
of patients were revealed to harbor protein changing mutations in exon 4on the mutational level. BCL11b mutations in pediatric
and adult patients had been reported in T-ALL in the
zinc finger structures of exon 4 [29,30,32,46]. In agreement
with these studies, we discovered a high rate (14%) of
BCL11b mutations in this large cohort of T-ALL pa-
tients. We found an association of immunophenotype
and mutation frequency: only 2% mutational rate in early
T-ALL patients and 19% mutational rate in thymic T-ALL
patients. Our results support a recent study in which
adult T-ALL patients characterized as “early/immature”
had fewer BCL11b mutations [32]. The number of BCL11bysis was performed by Sanger Sequencing in 178 T-ALL patients, 14%
of BCL11b.
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limiting the statistical significance regarding outcome. Also,
gene expression studies may be more sensitive to identify
patients with the specific outcome-associated phenotype
caused by BCL11b down-regulation.
Further studies are needed to fully understand the bio-
logical relevance of BCL11b mutations, and to explore
potential directed therapies.
In summary, we identified BCL11b expression as a potent
prognostic factor in the overall cohort and in particular in
the standard risk subgroup of thymic T-ALL. These find-
ings will help to identify patients with an enhanced risk of
failure to standard therapy, however, standardized detection
analyses of aberrant gene expression levels in a routine
diagnostic setting remains challenging. More importantly,
alterations in critical transcription factors contribute to
leukemogenesis and may be regarded as ideal candidates
for differentiation directed therapies in the future.
Methods
Patients
We analyzed diagnostic BM material of 195 adult T-ALL
patients sent to the GMALL reference laboratory [48].
Immunophenotyping of the samples was centrally per-
formed in the GMALL reference laboratory at the Charité,
University Hospital Berlin, Germany, as previously described
[49,50], and classified into the T-ALL subgroups: early
(n = 50), mature (n = 33) and thymic (n = 112). Of these,
169 T-ALL patients were consecutively enrolled in the
GMALL trials 06/99 and 07/2003 [51] with available
clinical follow-up data. Additionally, samples of healthy
adult donors were used, 13 BM samples, 13 CD34+
progenitors and nine CD3+ selected T-cell samples.
Written informed consent according to the declaration
of Helsinki had been given. Studies were approved by
the ethics board and registered in a public registry
(clincaltrials.gov NCT00199056, NCT0098991).
Sample preparation and qRT-PCR
Total RNA and DNA extractions were performed using
TRIzol reagent (Invitrogen) according to the manufacturer’s
instructions. To analyze BCL11b expression, complementary
DNA was synthesized and quantitative real-time polymerase
chain reaction (qRT-PCR) was performed, using Glucose-6-
Phosphate Isomerase (GPI) as internal control, as previously
described [52]. For BCL11b amplification forward pri-
mer AACCCGCAGCACTTGTCC, reverse-primer ATTT
GACACTGGCCACAGGT and probe FAM-CTCATCAC
CCCAGAGGCTGACCAT-BHQ1 spanning exons 1 and 2
were used. Expression levels of BCL11b were calcu-
lated using the mean of ΔCT from two replicates and
expressed as 2μ(ΔCT). The mRNA expression levels for
IGFBP7, WT1, BAALC, ERG, and GATA3 by qRT-PCR,
as well as mutation status of WT1 and NOTCH1 andTCR-rearrangements had been determined in previous
studies [12,34,35,52-54].Gene expression profiles
BCL11b-associated GEP of an independent set of 86 adult
T-ALL samples were generated from raw data obtained
from the Microarrays Innovations in Leukemia (MILE)
multicenter study (HG-U133 Plus 2.0; Affymetrix, Santa
Clara, CA, USA) [33]. For the GEP-analysis, samples were
divided into quartiles (Q) according to BCL11b expression
[median of the two probe sets (219528_s_at, 222895_s_at)].
To identify BCL11b-associated GEP signatures, the lowest
expression quartile (Q1) was compared to quartiles 2
to 4 united (Q2-4). Lists of genes with a 2-fold under-
or over-expression were generated. Statistical signifi-
cance was calculated by the non-parametric t-test with
a P-value ≤0.05. The data analyses were carried out with
GeneSpring software version 4.2 (Silicon Genetics,
Redwood City, CA, USA).Mutational analysis
Quantity and quality of genomic DNA was sufficient for
the mutational analysis of BCL11b in 178 T-ALL samples.
As previous studies had detected only very few mutations
outside exon 4, which harbors all six of the gene’s zinc
finger domains, we focused on this region [29,30]. Pri-
mer pairs were newly designed or used as previously
published for bidirectional Sanger sequencing of exon 4
(complete list see Additional file 1: Table S1) [29]. Geneious
version 5.4.3 software (Biomatters Ltd., Auckland, NZ)
was used for analysis.Additional file
Additional file 1: Statistical analysis. Figure S1. BCL11b mRNA expression
in T-ALL immunophenotypic subtypes. Figure S2. Kaplan–Meier analysis of
overall survival (OS) in T-ALL with respect to BCL11b mRNA expression.
Figure S3. Kaplan–Meier analysis of overall survival (OS) in T-ALL with
respect to BCL11b mutation status. Table S1. Primer sets designed for
human BCL11b exon 4 (NP_612808.1). Table S2. Probe sets up-regulated in
the BCL11b-low group of T-ALL patients. Table S3. Probe sets up-regulated in
the BCL11b-high group of T-ALL patients. Table S4. Molecular
characteristics of T-ALL patients with respect to BCL11b expression. Table S5.
Molecular characteristics of thymic GMALL T-ALL patients in respect to BCL11b
expression. Table S6. BCL11b exon 4 mutations in T-ALL. Table S7. Clinical
characteristics of GMALL T-ALL patients in respect to BCL11b
mutations. Table S8. Members of the German Multicenter Study Group for
Adult ALL Supplemental Methods: Statistics. References.Abbreviations
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